Friday Satellite Symposia

Friday Satellite Symposia

Friday Satellite Symposia (FSS) are industry-supported, CME-accredited symposia that are offered the day preceding the American Society of Hematology (ASH) annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the organizing company.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2025 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].


  • 1

    Morning Symposia

    7:00 a.m. - 10:00 a.m.
    Eastern time

    Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines To Improve Patient Outcomes in CLL/SLL

    This program is supported by AstraZeneca and Lilly. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Eastern time

    Join NCCN and CCO for an engaging virtual symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with chronic lymphocytic leukemia (CLL). This dynamic event features expert panel discussions and interactive case challenges to explore the latest treatment strategies across frontline and relapsed/refractory settings. Gain practical insights into selecting and sequencing covalent and noncovalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, incorporating molecular testing, and managing adverse events to support adherence. The program also delves into emerging therapies—including BTK degraders and bispecific antibodies —offering guidance on how to integrate these innovations into clinical practice through clinical trials. Engage directly with leading experts through live Q&A and learn how to deliver personalized, evidence-aligned CLL care.

    Chair:

    Sameer Parikh
    Mayo Clinic
    Rochester,  MN, United States

    Speaker:

    Matthew Cortese, MD, MPH
    Roswell Park Comprehensive Cancer Center
    Buffalo,  NY, United States

    Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma

    This program is supported by AstraZeneca, Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom R

    Join CCO and The Follicular Lymphoma Foundation for an innovative symposium spotlighting the latest advancements in relapsed/refractory (R/R) follicular lymphoma (FL) care. This dynamic session blends global patient survey insights, expert-led case discussions, and interactive polling to explore precision, chemotherapy-free strategies. Learn how to optimize the use of bispecific antibodies, CAR T-cell therapy, and novel targeted agents such as tazemetostat, tafasitamab, and BTK inhibitors. Engage directly with expert faculty in Q&A and townhall forums as they share practical guidance on therapy selection, sequencing, safety monitoring, and real-world implementation. Stay ahead of the curve with highlights of emerging clinical trial data and future directions in FL management. This symposium will challenge your clinical perspective, deepen your understanding of the shifting FL landscape, and empower you to deliver more personalized, evidence-informed care.

    Chairs:

    Laurie Sehn
    BC Cancer
    Vancouver,  BC, Canada

    Laurie Sehn
    University of British Columbia
    Vancouver,  BC, Canada

    Speakers:

    Peter Martin
    Weill Cornell Medicine
    New York,  NY, United States

    Gilles Salles
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Gilles Salles
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Consensus or Controversy?: Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia

    This program is supported by educational grants from Astellas, Kura Oncology Inc, Rigel Pharmaceuticals Inc, and additional to be announced.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency TUV

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with acute myeloid leukemia (AML). Five clinical investigators will serve as the faculty and one will moderate. RTP will also recruit 3 additional consulting clinical investigators who in addition to the faculty will complete a survey focused on controversial questions related to the management of AML. The responses from all 8 investigators will be graphically depicted and presented at the meeting to augment discussion and foster debate. The meeting agenda will be divided into 5 modules, each consisting of a review of survey results followed by a formal presentation of relevant research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion.. To make the activity available to a wider audience, the event will be webcast live as well as recorded and developed into an audio/video enduring CME resource promoted to ~46,500 oncology learners worldwide.

    Chairs:

    Harry Erba
    Duke University School of Medicine
    Durham,  NC, United States

    Harry Erba
    Duke University School of Medicine
    Durham,  NC, United States

    Speakers:

    Courtney DiNardo
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Amir Fathi
    Massachusetts General Hospital
    Boston,  MA, United States

    Alice Mims
    The Ohio State University Comprehensive Cancer Center
    Columbus,  OH, United States

    Alexander Perl
    University of Pennsylvania
    Philadelphia,  PA, United States

    Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and non-BCMA Immunotherapies

    This program is supported by independent medical education grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    In collaboration with HealthTree Foundation for Multiple Myeloma, this initiative—led and informed by the insights of three (3) expert hematology-oncology professionals—will use a series of interactive case-based Workshops to model team-based care solutions focusing on topical clinical questions and challenges related to optimal sequential care in RRMM. Throughout, the expert faculty will offer clear instructions for optimizing the RRMM treatment sequence, while addressing the following key topics:

    • The central role of BCMA-targeting cell therapies and off-the-shelf immunotherapeutics (eg, ADCs and bispecific antibodies) from early relapse to multi-refractory disease
    • Updated evidence supporting bispecific mechanisms targeting GPRC5D or FcRH5 and their established and future role in the management of patients with RRMM
    • Strategies for developing effective sequential treatment plans with BCMA and non-BCMA immunotherapies, while addressing unique aspects of care associated with their use throughout the patient treatment journey

    Chair:

    Sagar Lonial
    Winship Cancer Institute
    Atlanta,  GA, United States

    Speakers:

    Hans Lee
    Sarah Cannon Research Institute
    Nashville,  TN, United States

    Krina Patel
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    MASTERing MDS for Enhanced Patient Care: Modern Advances with STandard and Emerging, Risk-adapted Treatment

    This program is supported by educational grants from Bristol Myers Squibb and Geron Corporation.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Plaza Int'l DEFG

    In collaboration with our partner the HealthTree Foundation for Myelodysplastic Syndromes, this unique initiative, a panel of three (3) leading MDS experts will pair conversational case-based teaching with lessons of the latest evidence (including new data from ASCO, EHA, and ASH), to provide comprehensive and up-to-date recommendations for: 

    • Leveraging modern diagnostic classifications and molecular profiling to inform risk-adapted treatment planning in the context of modern goals of MDS care;
    • Integrating newer 1L standards into the management of LR MDS with anemia, from initiating treatment to ensuring adequate administration for long-term resolution of TD;
    • Upgrading the sequential care of patients with LR MDS and transfusion burden with the use of innovative MOAs; 
    • Navigating multifactorial decision-making for HR MDS that encompasses transplant candidacy, treatment convenience with oral HMA formulations, the presence of IDH1 mutations, and the emerging role of BCL2i-based combinations and XPO1i options.

    Chairs:

    Guillermo Garcia-Manero
    MD Anderson Cancer Center
    Houston,  TX, United States

    Guillermo Garcia-Manero
    MD Anderson Cancer Center
    Houston,  TX, United States

    Speaker:

    Maria Diez-Campelo
    Hospital Clínico Universitario de Salamanca
    Salamanca,  Spain, Spain

    Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes

    This program is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415D

    Through a collaboration with the HealthTree Foundation for AML, PeerView’s unique live event will:

    • Improve learners’ understanding of ongoing challenges in poor prognosis AML settings, including KMT2Ar disease and the impact of NPM1m in the RR setting;
    • Raise awareness of the MOA and clinical evidence to date with menin inhibitors in AML, including updates designed to capture rapidly changing evidence (such as findings reported at ASCO and EHA in 2025, and when available, data from ASH 2025 abstracts);
    • Use case-based guidance to facilitate the practical integration of menin inhibitors in the clinic across challenging KMT2Ar/NPM1m RR AML presentations, including through ongoing clinical trial opportunities;
    • Provide updates on different applications of menin inhibitor-based strategies or combinations in ND AML.

    Chairs:

    Navel Daver
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Navel Daver
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Speaker:

    Ghayas Issa
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Momentum in MDS: Making Progress and Shaping a Better Future

    This program is supported by The MDS Foundation, Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Tangerine Ballroom F2

    Recently, significant progress has been made in understanding the biology, genetics, and pathogenesis of MDS. These advances have led to meaningful developments in diagnosis, risk-stratification, and disease management—insights that will be reflected in the new international treatment guidelines, set to be presented and published by a leading global consortium of MDS experts.

    Among the evolving topics in the field is the role of morphology in modern medicine. This issue will be explored in depth along with the implications of germline mutations in MDS patients and how this knowledge necessitates a reassessment of current clinical approaches.

    The continued need for more effective therapies has also inspired the inclusion of a dedicated session on drug development, with a specific focus on the MDS pipeline.

    The program will also feature a patient-centered discussion to bridge the gap between scientific advancements and the lived experience of those navigating MDS in real-world settings.

    Chairs:

    Moshe Mittelman
    Tel-Aviv Sourasky Medical Center
    Tel Aviv,  Tel Aviv, Israel

    Valeria Santini
    AOU Careggi-University of Florence
    Florence,  Italy, Italy

    Speakers:

    Rafael Bejar
    University of California San Diego
    San Diego,  CA, United States

    Rena Buckstein
    Sunnybrook Health Sciences Centre
    North York,  ON, Canada

    Carmelo Gurnari
    University of Tor Vergata
    Rome,  Rome, Italy

    Robert Hasserjian
    Massachusetts General Hospital and Harvard Medical School
    Boston,  MA, United States

    Moshe Mittelman
    Tel-Aviv Sourasky Medical Center
    Tel Aviv,  Tel Aviv, Israel

    Valeria Santini
    AOU Careggi-University of Florence
    Florence,  Italy, Italy

    David Steensma
    Ajax Therapeutics
    Cambridge,  MA, United States

    Arjan Van de Loosdrecht
    VU University Medical Center
    Amsterdam,  Amsterdam, Netherlands

    Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies

    This program is supported by an independent educational grant from AstraZeneca.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415BC

    In collaboration with HealthTree Foundation for Acute Lymphocytic Leukemia (ALL), this PeerView Live initiative will provide perspectives on modern clinical standards in adult and pediatric ALL care, while preparing clinicians for future innovation with novel low affinity bispecific TCE strategies. Throughout the case-based Workshops, the expert faculty will discuss: 

    • The role of bispecific TCEs in current ALL practice guidelines, including in newly-diagnosed and R/R ALL and in Ph- and Ph+ settings across age populations
    • Utilizing evidence-based MRD monitoring to inform treatment choices with TCE, with a goal of deepening responses and improving long-term survival
    • Mechanistic rationale and evidence supporting low affinity bispecific TCE strategies designed to further augment therapeutic potency while reducing toxicity in R/R ALL 
    • Strategies to facilitate the integration of emerging bispecific TCEs (as they become available for use) into modern sequential ALL care

    Chair:

    Nicola Goekbuget
    University Hospital
    Frankfurt,  Germany, Germany

    Speakers:

    Ibrahim Aldoss
    City of Hope Duarte Cancer Center
    Duarte,  CA, United States

    Nicholas Short
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond

    This program is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415A

    In collaboration with HealthTree Foundation for NHL, this expert-led initiative will use a series of interactive case-based Workshops to model team-based care solutions focusing on topical clinical questions or problems related to NHL care, paired with Seminar segments designed to address the following topics:

    • The latest clinical evidence supporting the integration of modern and emerging CD20 x CD3 bispecific antibody platforms in diverse NHL subtypes; 
    • Strategies for personalizing treatment with bispecific antibodies for patients with DLBCL and FL in academic and community-based settings; 
    • Tools for addressing practical aspects of care with bispecifics such as step-up dosing, inpatient/outpatient administration, AE management, and supportive care planning;
    • Preview of next-steps with bispecifics in NHL, including use in earlier LOTs and in other lymphoma settings

    Chair:

    Max Topp
    Universitätsklinikum Würzburg
    Würzburg,  Germany, Germany

    Speaker:

    Sameh Gaballa
    Moffitt Cancer Center
    Tampa,  FL, United States

    Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies

    This program is supported by International PNH Interest Group


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Tangerine Ballroom F1

    The 2025 Symposium will address the impact of diagnostic and therapeutic advances over the past 143 years on recent advances in the management of patients with this rare but fascinating acquired genetic disorder involving hematopoietic stem cells. The program combines a historical perspective along with recent scientific data on the impact of therapies targeting several complement factors, proximal, distal; and both. The program will discuss the new scenario of  of broad treatment options, as well as ongoing scientific projects of the IPIG, such as the work underway to modernize diagnostic and therapeutic guidelines of novel guidelines and the development of an International, academic disease registry. The availability of appropriate diagnostics and therapies in different parts of the world.

    Chair:

    Morag Griffin
    International PNH Interest Group
    Altamonte Springs,  FL, United States

    Speakers:

    Regis Peffault de Latour
    International PNH Interest Group
    Altamonte Springs,  FL, United States

    Antonio Risitano
    International PNH Interest Group
    Altamonte Springs,  FL, United States

    Jeffrey Szer
    International PNH Interest Group
    Altamonte Springs,  FL, United States

    Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care

    This program is supported by independent educational grants from AstraZeneca, BeOne Medicines and Lilly.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Orlando Ballroom

     In collaboration with CLL Society, this expert-led activity will use a series of interactive case-based Workshops to model team-based care solutions focusing on topical clinical questions or problems related to CLL care. Throughout, the expert panelists will offer clear instructions on selecting customized therapy and preparing for emerging innovation in the field, while addressing the following key topics to facilitate a deeper understanding of modern CLL care:

    • The central role of continuous BTKi and TL standards for upfront CLL care, including newer TL BTK-BCL2i combinations;
    • Updates supporting sequential therapy with ncBTKi and cellular therapy in R/R disease;
    • The emerging role of newer modalities, including next-generation ncBTKi and BCL2i, BTK degraders, dual c/ncBTKi, and bispecifics in challenging pre-treated populations.

    Chair:

    Prof. John Gribben
    Barts and The London School of Medicine, Queen Mary, University of London
    London,  England, United Kingdom

    Speakers:

    Nicole Lamanna
    Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Irving Medical Cente
    New York,  NY, United States

    Nicole Lamanna
    Herbert Irving Comprehensive Cancer Center New York-Presbyterian/Columbia University Medical Center
    New York,  NY, United States

    Meghan Thompson
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    William Wierda
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    William Wierda
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data

    This program is supported by Indy Hematology Oncology


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W224CDGH

    This workshop will bring together experts in clinical research, policy, biostatistics, and patient advocacy to address the persistent underrepresentation of diverse populations in clinical trials. Through a multi-session format, the event will explore systemic, provider-level, and patient-level barriers to equitable trial access and participation.

    The first session will focus on structural solutions, highlighting how governance, industry partnerships, legal frameworks, and editorial policies can be aligned to drive inclusive research design and dissemination. Participants will gain insight into actionable strategies to embed equity at the institutional level.

    The second session will center on the provider’s role in promoting representation. Speakers will examine how to educate, recruit, and retain investigators committed to equitable research, as well as how biostatistical tools can identify and correct bias within trial design and execution.

    Finally, the third session will explore patient-level barriers to trial access, including restrictive eligibility criteria and historical mistrust. Presenters will share approaches to designing more inclusive protocols, building trust with underserved communities, and elevating the role of patient advocates.

    Together, these sessions will provide a comprehensive framework for creating more representative, ethical, and effective clinical research that leads to better outcomes for all populations.

    Chair:

    Ruemu Ejedafeta Birhiray
    Indy Hematology Education Inc
    Carmel,  IN, United States

    Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease

    This program is supported by an independent educational grant from AstraZeneca.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom S

    In collaboration with the HealthTree Foundation for Mantle Cell Lymphoma, PeerView’s unique Clinical Consults will link conversational case-based teaching with succinct supporting lectures to demonstrate how the latest evidence on 1L BTKi platforms is impacting decision-making for different MCL presentations and patient cohorts. Throughout, a panel of three (3) leading MCL experts will address the following topics:

    • The limitations of older 1L standards of care and the safety-efficacy lessons from the upfront use of first-generation BTKi combinations
    • The impact of recent regulatory updates and new evidence on frontline decisions with second-generation BTKi for patients with MCL who are fit for CIT
    • Emerging chemo-free BTKi options for frail or unfit patients (including combinations with CD20 antibodies, IMiDs and BCL2i)
    • The role of ASCT when BTKi are used as part of first-line therapy
    • How BTKi selectivity differences and head-to-head evidence further support the favorable tolerability of second-generation platforms
    • The implications of 1L BTKi use for treatment decisions in later-line care

    Chair:

    Martin Dreyling
    Ludwig-Maximilian-University Munich
    Munich,  Germany, Germany

    Speakers:

    Kami Maddocks
    Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    Colombus,  OH, United States

    Christine Ryan
    Dana-Farber Cancer Institute
    Boston,  MA, United States

    Rising to the Graft-versus-Host Challenge: Progress in Managing GVHD & Post-HCT Outcomes Across Hematologic Cancers

    This program is supported by educational grants from Incyte Corporation and Orca Bio.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W331

    In collaboration with BMT InfoNet, this conversational exchange of ideas, presented within a serial, case-based format, will engage learners with real-world scenarios designed to offer clear instructions on selecting customized therapy and preparing for emerging innovation in the field, while addressing the following key topics to facilitate a deeper understanding of the changing nature of GVHD management:

    • New evidence supporting innovative approaches to GVHD prophylaxis, including with JAK inhibitors, AAT, and high-precision T-cell therapies
    • Updates with approved and emerging therapies for the treatment of acute and chronic GVHD, including with novel MSC therapy, JAK and ROCK inhibitors, anti-CSF-1R or -CD6 antibodies, AAT, and ECP, among other innovations
    • Insights on the clinical implications of these advancements and how they can expand the transplant-eligible patient population, reduce NRM, and enhance RFS

    Chair:

    Zachariah DeFilipp
    Massachusetts General Hospital
    Boston,  MA, United States

    Speaker:

    Caspian Oliai
    UCLA Medical Center
    Los Angeles,  CA, United States

    Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

    This program is supported by GlaxoSmithKline, Johnson & Johnson, and Karyopharm Therapeutics. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    Join CCO for an engaging symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with multiple myeloma (MM). This dynamic event combines expert panel discussions and interactive case challenges to explore evolving treatment strategies across the MM continuum—from smoldering and newly diagnosed disease to relapsed/refractory settings. Gain practical insights into selecting and sequencing therapies such as triplet and quadruplet regimens, bispecific antibodies, and CAR T-cell products, while managing associated toxicities and coordinating care across practice settings. The program also addresses disparities in access to care and strategies to promote equitable treatment delivery. Engage directly with leading MM experts through live polling and Q&A sessions, apply the latest evidence to real-world cases, and preview key NCCN updates and ASH 2025 data. This symposium will deepen your understanding of guideline-aligned MM care, challenge your clinical decision-making, and empower you to optimize outcomes for diverse patient populations.

    Chair:

    Thomas Martin
    Helen Diller Family Comprehensive Cancer Center
    San Francisco,  CA, United States

    Speaker:

    Carol Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore,  MD, United States

    Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond

    This program is supported by Pharmacosmos Therapeutics Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W224ABEF

    Hematologists in both community and academic practice are increasingly being called upon to use antiangiogenic treatments to treat patients with inherited and acquired vascular bleeding disorders, including hereditary hemorrhagic telangiectasia (HHT), von Willebrand disease, acquired von Willebrand syndrome, and others. This symposium will discuss the role of angiogenesis in these bleeding disorders, how to optimally manage this bleeding with anti-angiogenic agents such as bevacizumab, pomalidomide, and pazopanib, and how to properly manage the complex and difficult chronic, severe iron deficiency anemia that complicates the course of these patients. Current and future potential antiangiogenic and coagulation-based treatments will be discussed by international leaders in the field.

    Chair:

    Hanny Al-Samkari
    Massachusetts General Hospital
    Boston,  MA, United States

    Speakers:

    Hanny Al-Samkari
    Massachusetts General Hospital
    Boston,  MA, United States

    Magdalena Lewandowska
    Innovative Hematology
    Indianapolis,  IN, United States

    Allyson Pishko
    University of Pennsylvania
    Philadelphia,  PA, United States

    Jenny Zhou
    University of California, San Diego
    San Diego,  CA, United States

  • 2

    Early Afternoon Symposia

    11:00 a.m. - 2:00 p.m.
    Eastern time

    A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges

    This program is supported by Novartis Pharmaceuticals Corporation. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency Ballroom R

    Join CCO for this engaging symposium reviewing the latest advancements in chronic phase chronic myeloid leukemia (CP-CML) management. This activity will feature experts discussing cases illustrating clinical application of the latest data and strategies to optimize the diagnosis, treatment, and management of CP-CML. Engage directly with leading experts through multiple discussion sessions, where you can present your questions and real-world cases for personalized guidance. Navigate the evolving evidence for individualized frontline CP-CML treatment, optimize response monitoring strategies, and gain insights into current recommendations for managing treatment intolerance and failure. This symposium promises to enrich your understanding of CP-CML, challenge your clinical acumen, and empower you to apply the latest evidence in your practice. Contribute to thought-provoking dialogues on CP-CML, shaping the discourse and enhancing collective expertise in this critical field.

    Chair:

    Jerald Radich
    Fred Hutchinson Cancer Center
    Seattle,  WA, United States

    Speakers:

    Neil P. Shah
    University of California
    San Francisco,  CA, United States

    B. Smith
    Johns Hopkins University School of Medicine
    Baltimore,  MD, United States

    Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL

    This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Genmab US, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W331

    2.0-hour Multi-Accredited Live Friday Satellite Symposium With Livestream and Interactive Polling

    Featuring patient testimonials to provide patient perspectives on receiving bispecific antibodies and discuss preferences, the expert faculty will guide the audience through nuances for navigating step-up dosing schedules and individualized treatment decision-making.

    Learners will have access to established resources from prior initiatives with bsAb therapy in DLBCL/FL to support optimal administration and management. Throughout the program, faculty will engage the on-site and virtual audiences by introducing gamified interactive polling with multiple-choice answers.

    The proposed event will utilize ConnectED by PRIME, an integrated live learning platform to connect healthcare providers with practice-changing education.

    Multi-Accredited On-Demand Video Podcasts of the Live Friday Satellite Symposium (2.0-hour Total Content)

    Following the live symposium, PRIME will develop four to six (4-6) enduring, on-demand video podcasts, each ranging from 0.25- to 0.5-hours in length. The podcasts will be created by extracting relevant portions from the recorded symposium livestream and condensing the content into stand-alone videos with distinct themes.

    Chair:

    Paolo Strati, MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Speakers:

    Douglas Burgoyne
    University of Utah College of Pharmacy
    Salt Lake City,  UT, United States

    Caron Jacobson, MD
    Dana Farber Cancer Institute
    Boston,  MA, United States

    Advancements in MPN and Lower-Risk MDS Management for the Community Clinic

    This program is supported by Incyte and Geron Corporation.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency Ballroom S

    This 90-minute symposium features 3 expert faculty in a lively roundtable discussion tailored for community clinicians. The session begins with a comprehensive overview to set the stage for understanding the complexities of ET, PV, MF, and LR-MDS, focusing on their evolving treatment landscapes. In "Today’s Community Clinic," the latest data and real-world evidence are presented, offering insights that are directly applicable to daily clinical practice. Experts will provide in-depth perspectives on how to integrate these findings into patient care, focusing on optimizing management strategies and addressing key considerations like risk assessment and treatment initiation. The final segment, "Tomorrow’s Promise," highlights important new data and key abstracts from ASH 2025 and their potential future clinical implications. The symposium concludes with key takeaways and an expert Q&A session, designed to reinforce learnings and equip clinicians with actionable insights, empowering them to effectively enhance patient care. 

    Chairs:

    John Mascarenhas
    Icahn School of Medicine at Mt Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    Speakers:

    Rami Komrokji
    Moffitt Cancer Center
    Tampa,  FL, United States

    Kristen Pettit
    University of Michigan
    Ann Arbor,  MI, United States

    Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy

    This program is supported by Novo Nordisk. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Orlando Ballroom

    Join CCO for an engaging symposium focused on advancing hemophilia care through non-factor replacement therapies. This dynamic event combines expert panel discussions, real-world case challenges, and insights from patients and community HCPs to explore the latest data on novel therapies including fitusiran, concizumab, marstacimab, and Mim8. Through interactive polling and audience Q&A, attendees will gain practical guidance on integrating these therapies into personalized care strategies for patients with moderate to severe hemophilia A and B. Discover how to navigate evolving safety profiles, improve joint health outcomes, and tailor treatment based on patient needs and preferences. This symposium offers a comprehensive view of current challenges, cutting-edge solutions, and future directions in hemophilia management, equipping you with actionable insights to improve clinical practice.

    Chairs:

    Steven Pipe
    University of Michigan
    Ann Arbor,  MI, United States

    Steven Pipe
    University of Michigan
    Ann Arbor,  MI, United States

    Speakers:

    Stacy Croteau
    Harvard Medical School
    Boston,  MA, United States

    Allison Wheeler
    University of Washington School of Medicine
    Seattle,  WA, United States

    Advancing Outcomes in Lymphoma Care: A MasterClass on Integrating the CAR T-Cell Therapies into Clinical Practice

    This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    Join CCO for an engaging symposium exploring the latest advancements in CAR T-cell therapy for relapsed/refractory (R/R) lymphomas. This dynamic event features expert-led discussions, real-world case challenges, and interactive polling to examine the expanding role of CAR T-cell therapies across B-cell lymphoma subtypes. Gain practical insights into patient selection, referral pathways, and coordination of care, along with strategies to manage acute and chronic toxicities such as CRS and ICANS. Learn how to educate patients and caregivers, implement survivorship planning, and optimize long-term outcomes. The symposium also highlights next-generation CAR T-cell innovations, including off-the-shelf products and combination strategies. Engage directly with faculty during live Q&A sessions, apply knowledge through interactive cases, and leave equipped to enhance care for patients receiving CAR T-cell therapy.

    Chair:

    Stephen Ansell
    Mayo Clinic Comprehensive Cancer Center
    Rochester,  MN, United States

    Speakers:

    Jeremy Abramson
    Harvard Medical School
    Cambridge,  MA, United States

    Jeremy Abramson
    Massachusetts General Hospital
    Boston,  MA, United States

    Cases & Conversations™ Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

    This program is supported by Geron Corporation (pending additional supporters).


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W224ABEF

    The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting. This satellite program will bring together 4 clinical experts to review the latest data regarding the management of MPNs, with short didactic presentations supplemented by panel discussions of challenging case scenarios. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chairs:

    John Mascarenhas
    Icahn School of Medicine at Mt Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    Speakers:

    Heinz Gisslinger
    Medical University of Vienna
    Vienna,  Wien, Austria

    Gabriela Hobbs
    Massachusetts General Hospital
    Boston,  MA, United States

    Gabriela Hobbs
    Harvard Medical School
    Cambridge,  MA, United States

    Ruben A. Mesa, MD
    Atrium Health Wake Forest Baptist Comprehensive Cancer Center
    Charlotte,  NC, United States

    Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

    This program is supported by educational grants from Abbvie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, BeOne Medicines, and Lilly.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency TUV

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with chronic lymphocytic leukemia (CLL). Four clinical investigators will serve as the faculty and one will be selected to moderate the program. Prior to the meeting, Research To Practice (RTP) will video record interviews with 3 general medical oncologists/hematologists (GMOs) who will present challenging CLL cases from their practices. To begin each of the 4 meeting modules, excerpts from the GMO interviews will be broadcast and the panelists will discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research related to the cases. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. The proceedings will be webcast live as well as recorded and developed into an enduring audio- and video-based CME resource. RTP will promote the event and enduring activity to ~46,500 oncology clinicians.

    Chair:

    Matthew Davids
    Dana-Farber Cancer Institute
    Boston,  MA, United States

    Speakers:

    Nicole Lamanna
    Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Irving Medical Cente
    New York,  NY, United States

    Nicole Lamanna
    Herbert Irving Comprehensive Cancer Center New York-Presbyterian/Columbia University Medical Center
    New York,  NY, United States

    Constantine Tam
    Monash University
    Melbourne,  South Australia, Australia

    William Wierda
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    William Wierda
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

    This program is supported by Amgen and Autolus.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F1

    • The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
      • This satellite program will bring together four clinical experts to review the latest data regarding the management of patients with ALL, with short didactic presentations supplemented by panel discussions of challenging case scenarios.
      • The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of ALL.

    Chairs:

    Elias Jabbour
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Elias Jabbour
    MD Anderson Cancer Center
    Houston,  TX, United States

    Speakers:

    Hagop Kantarjian
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Aaron Logan, MD, PhD
    University of California, San Francisco
    San Francisco,  CA, United States

    Aaron Logan, MD, PhD
    University of California, San Francisco
    San Francisco,  CA, United States

    Rob Pieters
    Princess Maxima Center for Pediatric Oncology
    Utrecht,  Utrecht, Netherlands

    Claire Roddie
    University College London (UCL) Hospitals
    London,  England, United Kingdom

    Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

    This program is supported by Kura Oncology, Inc. and Rigel Pharmaceuticals, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F2

    1. CME- Certified Hybrid Satellite Symposium:
    • The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
      • This satellite program will bring together four clinical experts to review the latest data regarding the management of AML, with short didactic presentations supplemented by panel discussions of challenging case scenarios.
      • The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of AML.
    • To further enhance the integration of recent data into practice, the program will feature an interactive polling and question-and-answer sessions between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chairs:

    Navel Daver
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Navel Daver
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Speakers:

    Konstanze Döhner
    Ulm University
    Ulm,  Ulm, Germany

    Catherine Lai
    Penn Medicine
    Philadelphia,  PA, United States

    Amer Zeidan
    Yale Cancer Center
    New Haven,  CT, United States

    Joshua Zeidner
    The University of North Carolina Lineberger
    Chapel Hill,  NC, United States

    Joshua Zeidner
    University of North Carolina School of Medicine
    Chapel Hill,  NC, United States

    Medical Crossfire®Integrating T-Cell Engaging-Therapies in B-Cell Malignancies: Current Updates and Future Directions

    This program is supported by This program is pending support


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F3-4

    • The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
      • This satellite program will bring together four clinical experts to review the latest data regarding the use of T-cell engaging therapies, with short didactic presentations supplemented by panel discussions of challenging case scenarios.

    Chair:

    Bijal Shah
    Moffitt
    Tampa,  FL, United States

    Speakers:

    Anita Kumar
    Memorial Sloan Kettering Cancer Center
    Bernards Township,  NJ, United States

    Tycel Jovelle Phillips, MD, FASCO
    City of Hope
    Duarte,  CA, United States

    Rare Clinical Spotlight: Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria

    This program is supported by Recordati Rare Diseases


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    This 90-minute, interactive live symposium will feature 6 expert faculty representing the three rare hematologic diseases, Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria. The program will emulate a day in the clinic for the community hematologist using patient cases to highlight key clinical decision making. Expert faculty will include an emphasis on key considerations for the diagnosis and treatment of these patients, including proper diagnostic workup, understanding the importance of proper referrals, identifying the best treatment options, and applying practical strategies, including dosing, duration, and adverse event management to improve patient outcomes. The importance of communication will patients as well as collaboration with members of the multidisciplinary team will also be emphasized. Interactive polling questions embedded within the cases will allow the audience to stay engaged throughout the program.

    Speakers:

    Catherine Broome
    Georgetown University
    Washington DC,  DC, United States

    Angelika Erwin
    Cleveland Clinic
    Cleveland,  OH, United States

    Sudipto Mukherjee
    Cleveland Clinic Taussig Cancer Institute
    Cleveland,  OH, United States

    Ariela Noy
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Bruce Wang
    University of California, San Francisco
    San Francisco,  CA, United States

    Ilene Weitz
    Keck School of Medicine of USC
    Los Angeles,  CA, United States

    Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition

    This program is supported by Novo Nordisk Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W224CDGH

    Integritas Communications (INTEGRITAS) respectfully requests to plan, produce, certify, and distribute an educational initiative titled Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management -- A CME COMPETE™: SCD Edition activity. The program will include the following activity components:

    * A live continuing medical education (CME) symposium held during the Friday Satellite Symposium (FSS) on December 5, 2025, preceding the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL.

    * CME COMPETE: SCD Edition™ is an innovative, gamified, team-based activity designed to engage and educate attendees through high-energy competition. This interactive format enhances healthcare providers' (HCPs) ability to retain key clinical knowledge while fostering critical thinking and problem-solving skills.

    --The symposium will use a Test--Teach--Compete format to integrate didactic presentations on current standards of care and emerging advances in Sickle Cell Disease (SCD) with dynamic gamification elements to maximize engagement. Expert-led discussions will provide real-time interpretation of the latest clinical data, guiding best practices in SCD management. A key feature of the program is its interactive case challenges, allowing participants to apply their knowledge in real-world scenarios.

    --The overall program goal is to enhance HCPs' ability to apply the latest evidence-based strategies in comprehensive SCD management, ensuring optimal patient outcomes. The program will address unmet needs beyond pain crises, guide understanding and integration of novel and emerging therapies, and emphasize multidisciplinary care coordination across the patient journey. Collaboration with experts in SCD treatment will ensure the education remains scientifically rigorous, clinically relevant, and aligned with the needs of HCPs who care for patients with SCD.

    * Livestream and "Same-Day" On-Demand Symposium will be available during and immediately following the live meeting and for the first month following the live event to provide access to the meeting content, with CME credit available, for those who were not able to attend the live session.

    * The activity will be hosted on a dedicated landing page, which will include our "Ask the Expert" chat box. Learners will be able to submit questions in the month following the program launch, after which we will record faculty responses and email a compilation video to all clinician participants.

    * Take-Away Resources will be provided to all attendees in the following formats:

    --A printed "Clinician's Guide" designed to serve as a point-of-care reference tool to optimize the management of patients with SCD. A link to a printable digital version will be provided to virtual learners.

    --A link to an online Clinical Resource Center will be made available to provide learners access to additional educational assets, including the slide deck and links to the most relevant references, following the live or online program. The link may also be called out on the symposium promotional materials distributed to all ASH attendees to broaden awareness even among those unable to attend the session.

    * An enduring online CME COMPETE: SCD Edition™ program will be curated from components of the live session, with a video-based webcast capturing faculty discussions, didactic content, clinical data, as well as case discussions and external resources discussed during the activity. This on-demand, online program will extend the reach of the educational content via distribution on NexusMedX.com as well as on ExchangeCME.com.

    Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma Care: A Case Based Discussion

    This program is supported by Genmab US, Inc. and AbbVie


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W311EFGH

    This practice-focused 90-minute symposium will feature 2 expert hematologists/oncologists and a patient advocate (eg, Lymphoma Coalition) as they review the evolving role of bispecific antibodies in the treatment of R/R FL, with a focus on their use in the 2+ line setting. Patient clinical cases will set the stage for expert presentations and panel discussions on real-world challenges and best practices for integrating these agents into clinical practice, ensuring both evidence based and patient-centered strategies. 

    Chairs:

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medicine
    Omaha,  NE, United States

    Speakers:

    Natacha Bolaños
    Lymphoma Coalition
    Madrid,  n/a, Spain

    Chan Cheah
    Breakthrough Haematology
    Nedlands,  Western Australia, Australia

    Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management

    This program is supported by Deciphera, a member of ONO Pharma


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Plaza Int'l DEFG

    This practice-focused, 90-minute symposium will feature three expert faculty in the field of PCNSL for an in-depth look at relapsed/refractory (R/R) disease. A review of current treatment options as well as a section on targeted therapies in PCNSL will lead off this program. A unique “Bringing PCNSL Into the Clinic” section will feature expert presentations and panel discussions on real-world challenges and best practices for treating this rare disease into clinical practice, ensuring both evidence-based and patient-centered strategies. Recent data highlights as well as an open audience Q&A and panel discussion will ensure maximum audience participation.  This program will also focus on advancements for the evolving management of R/R PCNSL. 

    Chair:

    Christopher DeAngelo
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Speakers:

    Amitkumar Mehta
    University of Alabama at Birmingham
    Birmingham,  AL, United States

    Ashley Sumrall
    Atrium Health
    Charlotte,  NC, United States

    The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment

    This program is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol Myers Squibb, Legend Biotech, and Kite Pharma, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W230

    This live symposium will highlight cutting-edge clinical data and research findings associated with CAR T-cell therapy in multiple myeloma (MM). Experts will deliver in-depth analyses of the latest developments, focusing on real-world clinical implications, and attendees will learn about the most current and impactful data that will enhance their ability to use CAR T-cell therapies for MM. A series of brief patient case studies will set the stage and launch faculty presentations and panel discussions. The faculty will offer their interpretations of the data, share practical insights, and address potential challenges in applying the findings to patient care. Attendees will use mobile technology to participate in case studies, submit questions to faculty, and explore how new evidence can be translated into improved clinical outcomes. This combination of data presentation and faculty feedback contributes to deeper engagement and encourages practical application of learnings.

    Chair:

    Luciano Jose Costa
    University of Alabama at Birmingham
    Birmingham,  AL, United States

    Speakers:

    Michael Bishop
    University of Chicago
    Chicago,  IL, United States

    Binod Dhakal
    Medical College of Wisconsin
    Milwaukee,  WI, United States

  • 3

    Late Afternoon Symposia

    3:00 p.m. - 6:00 p.m.
    Eastern time

    Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non-Hematological Outcomes

    This program is supported by an educational grant from Sanofi.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency Ballroom R

    Up to 20% of pediatric patients and up to 70% of adult patients with immune thrombocytopenia have chronic disease, persisting for at least 12 months. Though available treatment options have seen some success, they are limited in their ability to address the underlying autoimmune platelet destruction etiology of ITP and often possess negative risk profiles. As a result, patients often live with uncontrolled hematological and non-hematological disease burden, including fatigue and cognitive impairment. Emerging therapies, such as Bruton’s tyrosine kinase inhibitors (BTKi), FcRN blockers, and other strategies, may offer more effective, durable, and safer treatment options to address the multi-faceted burden of ITP. Ensuring patients can access these novel therapies requires efforts to remain up-to-date with their supporting scientific data and understand principles for integrating treatments into practice. Through a dynamic format that integrates evidence-based presentations, panel discussions, and clinical cases, expert faculty participating in this symposium will bring evolving science to life and provide clinical insights to evolving strategies to address hematological and non-hematological ITP manifestations and improve the patient experience.

    Learning objectives:

    o   Describe the role of systemic inflammation in the development and progression of ASCVD and CKD, including the bidirectional relationship between these conditions 

    o   Apply evidence-based strategies to optimize the use of hsCRP in assessing residual inflammatory risk and guiding treatment decisions in ASCVD and CKD 

    o   Assess emerging therapeutic strategies that target residual inflammatory risk to reduce CV events in patients with ASCVD and CKD, including their mechanisms of action, efficacy, and safety  

    o   Evaluate the clinical implications of emerging inflammation-targeted therapies in ASCVD and CKD, including prospective considerations for clinical integration and their potential impact on patient outcomes

    Chair:

    David Kuter
    Massachusetts General Hospital
    Boston,  MA, United States

    Speakers:

    Nicola Cooper
    Imperial College Healthcare; NHS Trust
    London,  England, United Kingdom

    Cindy Neunert
    Columbia University Irving Medical Center
    New York,  NY, United States

    Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management

    This program is supported by Alnylam Pharmaceuticals, Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    This 90-minute symposium will feature 3 expert faculty. The symposium will be structured around a "Learn, Discuss, Ask" format, where each segment encompasses the faculty giving a presentation (learn), they then engage in a panel discussion using case examples and/or real-world experiences (discuss), and end the segment with polling questions and an audience Q&A opportunity (ask). It offers multiple opportunities for direct engagement with the expert faculty, aiming to deepen the understanding of disease considerations and clinical evidence surrounding treatments for AHP.

    Chair:

    Brendan Mcguire
    University of Alabama at Birmingham
    Birmingham,  AL, United States

    Speakers:

    Rebecca Karp
    Massachusetts General Hospital
    Boston,  MA, United States

    Akshata Moghe
    University of Texas Health Science Center
    Houston,  TX, United States

    Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access

    This program is supported by Roswell Park Alliance Foundation, BMS, Legend Biotech, BeOne (formerly Biogene) and Regeneron. Pending confirmation from Kite and Novartis.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W230

    Chimeric antigen receptor (CAR) T cell therapy has reshaped the treatment landscape for B-cell malignancies, yet major clinical and implementation challenges persist. This symposium addresses critical unmet needs in the field: optimizing CAR T cells in real-world practice, sequencing therapies, managing post-relapse scenarios, understanding resistance biology, and expanding access to underserved populations. Given the rapid evolution of therapies and shifting treatment paradigms, there is an urgent need to equip clinicians and researchers with expert guidance on how to navigate these complex decisions and translate new data into patient-centered care.

    BRINGING EMERGING TREATMENTS TO ALL PATIENTS: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices

    This program is supported by Indy Hematology Alliance


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Valencia Room W415BC

    Innovative immune effector therapies, including CAR T-cell and bi-specific antibody treatments, have transformed cancer care but remain largely inaccessible to community oncology practices. This symposium is dedicated to bridging this gap by establishing the necessary infrastructure, protocols, and training to safely and effectively administer these lifesaving therapies in community settings. By promoting equitable access, fostering clinical trial participation, and supporting diverse patient populations, we aim to reduce disparities and expand the reach of modern cellular therapies.

    Chairs:

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medicine
    Omaha,  NE, United States

    Speakers:

    Ralph Vincent Boccia
    The Center for Cancer and Blood Disorders
    Bethesda,  MD, United States

    Tara Graff
    Mission Cancer and Blood
    Des Moines,  IA, United States

    Frederick Locke
    Moffitt Cancer Center
    Tampa,  FL, United States

    Nikhil Munshi
    Dana-Farber Cancer Institute
    Boston,  MA, United States

    Richard Stone
    Dana-Farber Cancer Institute
    Boston,  MA, United States

    Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment

    This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Kura and Syndax.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W331

    1.5-hour Multi-Accredited Live Friday Satellite Symposium With Livestream and Interactive Polling

    Expert faculty will highlight the biological rationale and clinical evidence for the use of menin inhibitors in the treatment of KMT2A-rearranged and NPM1-mutated AML, identification of appropriate patients, integration of menin inhibitors into the treatment paradigm, and identification and development of emerging combination regimens. Case-based discussions will support learners in identifying patients eligible for novel menin inhibitor therapy, as well as recognizing and managing treatment-related toxicities such as differentiation syndrome and QTc prolongation. Throughout the program, faculty will engage the on-site and virtual audiences by introducing gamified interactive polling with multiple-choice answers.

    Learners will have access to a downloadable Clinical Trial Pocket Guide designed to support clinicians in differentiating between novel menin inhibitors, and will provide a concise overview of novel menin inhibitor combination treatment strategies in clinical trials.

    The proposed event will utilize ConnectED by PRIME, an integrated live learning platform

    to connect healthcare providers with practice-changing education.


    Multi-Accredited On-Demand Video Podcasts of the Live Friday Satellite Symposium (1.5-hour Total Content)

    Following the live symposium, PRIME will develop two to four (2-4) enduring, on-demand video podcasts, each ranging from 0.25- to 0.5-hours in length. The podcasts will be created by extracting relevant portions from the recorded symposium livestream and condensing the content into stand-alone videos with distinct themes.

    Chairs:

    Joshua Zeidner
    The University of North Carolina Lineberger
    Chapel Hill,  NC, United States

    Joshua Zeidner
    University of North Carolina School of Medicine
    Chapel Hill,  NC, United States

    Speaker:

    Justin Watts
    University of Miami/Sylvester Comprehensive Cancer Center (SCCC)
    Miami,  FL, United States

    Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis

    This program is supported by educational grants from Bristol Myers Squibb, GSK, Incyte Corporation, and additional to be announced.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency TUV

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis (MF). 5 clinical investigators will serve as the faculty and 1 will be selected to moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with MF. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. The proceedings will be webcast live as well as recorded and developed into an enduring audio- and video-based CME resource. RTP will promote the event and enduring activity to ~46,500 oncology clinicians.

    Chair:

    Andrew Kuykendall
    Moffitt Cancer Center
    Tampa,  FL, United States

    Speakers:

    Professor Claire Harrison
    Guy’s and St Thomas’ NHS Foundation Trust
    London,  London, United Kingdom

    Ruben Mesa
    Wake Forest University School of Medicine
    Winston-Salem,  NC, United States

    Stephen Oh
    Washington University School of Medicine
    St Louis,  MO, United States

    Raajit Rampal
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Raajit Rampal
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes

    This program is supported by an independent medical education grant from Sanofi.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Valencia Room W415A

    Hemophilia is a rare, chronic disease caused by a deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B) in which impaired coagulation leads to recurrent bleeding into joints, muscles, and internal organs, resulting in long-term complications such as chronic arthropathy. Recently approved and emerging therapies have the potential to transform care for patients with hemophilia A and B, but providers have difficulty keeping pace with the latest advances. To further complicate matters, the recent treatment guideline issued by the International Society on Thrombosis and Haemostasis (ISTH) contradicted previous guideline recommendations regarding topics such as which patients should receive prophylaxis; in addition, it failed to address the benefit of newer therapies. In light of these issues, the proposed CME-approved live hemophilia panel discussion, to take place as a Friday Satellite Symposium at the 67th American Society of Hematology (ASH) Annual Meeting, will arm hematologists and other members of the interprofessional hemophilia care team with tools they require to apply the latest evidence to the tailored management of hemophilia A and B.

    This Friday Satellite Symposium will feature a panel of experts in the management of hemophilia in children and adults. The hemophilia panel will be charged with re-examining the guidelines and incorporating these into their own recommendations in the following areas:

    • Defining appropriate treatment goals for patients with hemophilia
    • Identifying patient-relevant outcomes by which prophylactic agents should be evaluated
    • Determining which patients with hemophilia should receive prophylaxis
    • Comparing prophylactic options for hemophilia A and B: short- and long-term safety, patient-relevant efficacy outcomes in different populations, and therapeutic selection considerations
    • Appraising prophylaxis protocols for major invasive procedures
    • Reducing the burden of hemophilia treatment and improving adherence
    • Utilizing pharmacokinetic-guided prophylaxis
    • Enabling increased physical activity without risk of bleeds
    • Engaging patients in shared decision making

    Case studies with audience polling will be used to refine the recommendations and foster interactive discussions between the hemophilia panel members and learners. Discussions will focus on the implementation of management plans based on the panel’s recommendations, as well as patient and disease characteristics, prior lines of therapy, shared decision making, response assessment, and quality-of-life concerns. 

    Following the Friday Satellite Symposium, the panel recommendations will be written into a position statement and submitted to a peer-reviewed journal for publication to be disseminated. This will summarize the most relevant analyses and actionable items engendered by the hemophilia panel discussion, with the educational goal of providing learners with an evidence-based overview of expert recommendations for the management hemophilia within the context of patient-centered care.

    Chair:

    Robert Sidonio, Jr.
    Emory University School of Medicine
    Atlanta,  GA, United States

    Medical Crossfire® Navigating the Chronic Myeloid Leukemia Landscape: Treatment Strategies, Mechanisms, and Patient-Centered Care

    This program is supported by Takeda Pharmaceuticals USA, Inc (pending additional supporters).


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F1

    • The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
      • This satellite program will bring together four clinical experts to review the latest data regarding the management of CML, with short didactic lectures supplemented by panel discussions of pertinent clinical challenges, emerging treatment strategies, and real-world applications of current guidelines.
    • To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Jorge Cortes
    Georgia Cancer Center
    Augusta,  GA, United States

    Speakers:

    Jane Apperley
    Department of Haematology Hammersmith Hospital Imperial College
    London,  United Kingdom, United Kingdom

    Michael Mauro
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Neil Shah
    UCSF Helen Diller Comprehensive Cancer Center
    San Francisco,  CA, United States

    Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care - Targeted Strategies to Elevate Patient Outcomes

    This program is supported by Orca Bio.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F2

    This program convenes a panel of world-renowned expert faculty in GVHD to tackle pressing clinical issues. The panel offers participants invaluable clinical pearls, practical strategies, and insights from leaders in the field. The dynamic format encourages active engagement, challenging participants to critically evaluate their practices and apply the latest evidence to improve patient care.

    Chair:

    Mehdi Hamadani
    Medical College of Wisconsin
    Milwuakee,  WI, United States

    Speakers:

    Amin Alousi
    The University of Texas MD Anderson Cancer Center
    Houston,  TX, United States

    Corey Cutler
    Dana-Farber Cancer Institute
    Boston,  MA, United States

    Anna Sureda Balarí
    Institut Català d'Oncologia - Hospital Duran i Reynals
    Barcelona,  Barcelona, Spain

    Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs

    This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    Join CCO for an interactive, case-based symposium exploring the evolving role of CELMoD therapy in multiple myeloma (MM). Through a unique “Two Truths and a Myth” gameshow format, expert faculty will unpack key mechanistic differences between CELMoDs and IMiDs, review pivotal trial data for iberdomide and mezigdomide, and discuss the clinical implications of MRD-negative complete response as a surrogate endpoint. Participate in dynamic faculty Q&A sessions and real-world patient case challenges that highlight how CELMoDs may be integrated into near-future treatment paradigms and clinical trials. Prepare for the next wave of innovation in MM care.

    Chair:

    Niels W.C.J. Van De Donk
    Amsterdam University Medical Center
    Amsterdam,  N/A, Netherlands

    Speakers:

    Jesús Berdeja
    Greco-Hainsworth Centers for Research
    Nashville,  TN, United States

    Amrita Krishnan
    City of Hope Cancer Center
    Irvine,  CA, United States

    PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

    This program is supported by Sanofi.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F3-4

    • This satellite program will bring together four clinical experts to review real-world cases that synthesize recent data from landmark trials of new approaches for the management of NDMM into practical insights for clinicians to implement in routine practice. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Ajai Chari
    University of California, San Francisco
    San Francisco,  CA, United States

    Speakers:

    Caitlin Costello
    University of California, San Diego
    San Diego,  CA, United States

    María-Victoria Mateos
    University of Salamanca, Spain
    Salamanca,  Salamanca, Spain

    Mohamad Mohty
    Saint-Antoine Hospital Sorbonne University
    Paris,  Paris, France

    Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case Based Discussion

    This program is supported by Genmab US, Inc. and AbbVie


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W311EFGH

    This practice-focused, 90-minute symposium will feature 2 expert hematologists/oncologists and a patient advocate (eg, Leukemia and Lymphoma Society) as they review the evolving role of bispecific antibodies in the treatment of R/R DLBCL, with a focus on their use in the 2+ line setting. Patient clinical cases will set the stage for expert presentations and panel discussions on real-world challenges and best practices for integrating these agents into clinical practice, ensuring both evidence-based and patient-centered strategies.

    Chair:

    Joshua Brody, MD
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    Speakers:

    Elizabeth Brem
    UCI Health
    Orange,  CA, United States

    Lorna Warwick
    Lymphoma Coalition
    Mississauga,  ON, Canada

    Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    This program is supported by Novartis Pharmaceuticals.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W224ABEF

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare genetic hematologic disorder that stems from deficient proteins that mediate the complement pathway. [DeZern 2015] Unregulated complement activity leads to its hallmark manifestations of hemolytic anemia, bone marrow failure, and elevated risk of thrombosis. The clinical symptoms vary considerably between affected individuals. Patients may present with unexplained hemolytic anemia, fatigue, jaundice, and red/pink/dark urine, while others experience headaches, dysphagia, scleral icterus, or confusion. Approximately 10-20 people per million worldwide live with PNH. [Cancado 2021] Although it can occur at any age, PNH is often diagnosed between the ages of 30 to 40. [Hill 2017]; [Schrezenmeier 2020].

    Before the availability of effective treatments, the median survival was just 15 to 20 years, with thrombosis as the leading cause of death. [Bektas 2020a] The development of targeted complement inhibitors has transformed outcomes for patients with PNH, enabling patients to achieve life expectancies similar to age-matched controls. [Bodo 2023]

  • 4

    Evening Symposia

    7:00 p.m. - 10:00 p.m.
    Eastern time

    EXPERT SECOND OPINION: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    This program is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt - Regency TUV

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focused on the integration of novel approaches into the care of patients with DLBCL and FL. 5 investigators will serve as the faculty and 1 will be selected to moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with DLBCL or FL treated with novel agents/strategies. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. The proceedings will be webcast live as well as recorded and developed into an enduring web- and mobile-based CME resource promoted to ~46,500 oncology clinicians.

    Chairs:

    Jeremy Abramson
    Harvard Medical School
    Cambridge,  MA, United States

    Jeremy Abramson
    Massachusetts General Hospital
    Boston,  MA, United States

    Speakers:

    Nancy Bartlett
    Washington University School of Medicine
    St Louis,  MO, United States

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medical Center
    Omaha,  NE, United States

    Matthew Lunning
    University of Nebraska Medicine
    Omaha,  NE, United States

    Gilles Salles
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Gilles Salles
    Memorial Sloan Kettering Cancer Center
    New York,  NY, United States

    Laurie Sehn
    BC Cancer
    Vancouver,  BC, Canada

    Laurie Sehn
    University of British Columbia
    Vancouver,  BC, Canada

    Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice

    This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Geron and Karyopharm


    7:00 p.m. - 10:00 p.m. Eastern time
    OCCC - W331

    2.0-hour Multi-Accredited Live Friday Satellite Symposium With Livestream and Interactive Polling

    Faculty will guide learners in evaluating the latest clinical evidence for Hot Topics in MF care, including (1) selecting and sequencing JAK inhibitor therapy, (2) managing MF-related anemia, and (3) emerging non-JAK inhibitor therapies.

    Featuring case-based discussions with gamified interactive polling to stimulate patient-centered treatment decision-making for translation into clinical practice, and live Q&A sessions to address ‘top of mind’ questions posed by the audience.The proposed event will utilize ConnectED by PRIME, an integrated live learning platform to connect healthcare providers with practice-changing education.

    Multi-Accredited On-Demand Video Podcasts of the Live Friday Satellite Symposium (2.0-hour Total Content).

    Following the live symposium, PRIME will develop three to six (3-6) enduring, on-demand video podcasts, each ranging from 0.25- to 0.5-hours in length. The podcasts will be created by extracting relevant portions from the recorded symposium livestream and condensing the content into stand-alone videos with distinct themes.

    Chairs:

    John Mascarenhas
    Icahn School of Medicine at Mt Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

    John Mascarenhas
    Icahn School of Medicine at Mount Sinai
    New York,  NY, United States

67th ASH Annual Meeting and exposition

San Diego Convention Center

Registration for ASH members is now open!

Registration for non-members, groups, exhibitors, and media will open on August 13, 2025, at 11:00 a.m. Eastern time.

View Additional Information

Explore the Annual Meeting